Mingren Pharma

Kaifeng Mingren Pharmaceutical is a China-based pharmaceutical manufacturer focused on APIs, pharmaceutical intermediates, finished dosage formulations, and CDMO services. The company states it was established in 2002 and operates manufacturing facilities in Kaifeng, with additional R&D presence in Shanghai and other production operations in Gansu and Jiangsu. Its marketed and catalog portfolio appears to center on small-molecule APIs and related intermediates, with examples including phloroglucinol derivatives, nafamostat mesylate, epalrestat, isavuconazonium sulfate, atogepant, ubrogepant, tegoprazan, selumetinib, and doxofylline. The company also highlights production capabilities for sterile APIs, polypeptide APIs, lyophilized powder injections, tablets, granules, and powder injections. Publicly available information supports characterizing Mingren primarily as a commercial-stage pharmaceutical manufacturing and supply company rather than a venture-backed clinical biotech developing a disclosed novel therapeutic pipeline.